Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPN01
- Development stage
- Phase 1
- Lead developer
- Beijing Shengguangna Medical Technology
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
SPN01 is an investigational intravenous injectable drug developed by Beijing SonoPhotoNano Medical Technology. It is classified as an antineoplastic agent intended primarily for the treatment of colorectal cancer. The exact mechanism of action of SPN01 has not been defined publicly. The drug is currently in early clinical development, with a Phase 1 trial planned to evaluate its safety, tolerability, pharmacokinetics, preliminary efficacy in colorectal cancer patients, effects on QTc interval, and metabolic characteristics in humans. This study aims to establish foundational data for further development[1][2][3].
Beyond the preview
Go deeper on SPN01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPN01.